HELP

CybinB

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-07-18

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

25%

Probability

Target price

$9.50

+31.0% vs current

Most likely

Base case

45%

Probability

Target price

$6.00

-17.2% vs current

B-

Bear case

30%

Probability

Target price

$3.25

-55.2% vs current

AI sentiment snapshot

Latest data as of 2026-07-09

AI commentary

Primary company materials in the stored earnings context support the June 29, 2026 fiscal-year update and pipeline milestones, but the broader evidence set remains thin. The stock anchor was $6.23 on July 8, 2026. With no usable social packet, no SEC excerpt in the packet, limited external coverage, and only loose same-sector micro-cap peer candidates, sentiment should be treated as cautious monitoring rather than a standard-conviction directional setup.

RankAlpha Sentiment Codex - 2026-07-09

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-09-30catalystPost-offering cash reduces immediate financing pressure but dilution remains part of the setupHigh impact

Primary company materials show $157.3 million of cash at March 31, 2026 and completion of a $50 million underwritten offering on June 25, 2026; that helps near-term runway, but the equity-financed model keeps dilution and future capital needs in focus [#PR-EARNINGS-2026-06-29].

2026-12-15eventHLP003 Phase 3 APPROACH topline data targeted for Q4 2026High impact

Helus Pharma, the commercial operating name of Cybin Inc., said the APPROACH pivotal Phase 3 study in MDD has surpassed 88% enrollment and remains on track for a Q4 2026 topline readout, which is the clearest binary value driver in the packet [#PR-EARNINGS-2026-06-29].

2028-06-30catalystSecond Phase 3 study and 2028 NDA path can extend upside if execution holdsHigh impact

The company said the June 2026 financing is intended to support EMBRACE, the second Phase 3 HLP003 trial, with a potential U.S. NDA path in 2028; that adds duration to the thesis but remains heavily execution-dependent for a micro-cap biotech [#PR-EARNINGS-2026-06-29].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-07-09 • Updated nightlySource: Internal modelMethodology